Another epigenetic biomarker identified was DNA hypermethylation at HOXA4. Both HOXA4 hypermethylation during CLL progression and relapse and loss of HOXA4 expression were associated with resistance to chemotherapeutic agents including fludarabine[64]. Here, HOXA4 is linked to B-cell chronic lymphocytic leukemia.